文献速递免疫规划

双价HPV疫苗两剂程序免疫应答持久性随访研究

Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule.
PubMed 文献 · Vaccine · 2018-10-28

荷兰常规免疫规划中按0、6月两剂程序接种双价HPV疫苗的女孩队列,采集首剂后7、12、24月血样(n=56),检测七种型别抗体浓度与亲和力。HPV16/18血清阳性率至24月保持100%,GMC下降但仍高;其他型别血清阳性率下降,亲和力低。

要点

  • 两剂双价HPV疫苗后24月内HPV16/18血清阳性率保持100%。
  • HPV16/18的GMC随时间下降但仍维持较高水平。
  • 疫苗型别抗体高亲和力比例>75%,其他型别<35%。

核心结论

  • 两剂双价HPV疫苗后24月内HPV16/18抗体浓度下降但仍高且血清阳性率100%,疫苗型别抗体亲和力>75%。

研究设计与样本

  • 队列研究,荷兰常规免疫规划中按0、6月两剂程序接种双价HPV疫苗的女孩,首剂后7、12、24月采血并收集问卷(n=56)。

主要发现

  • HPV16/18血清阳性率至24月为100%,HPV31/33/45/52/58血清阳性率下降,其中HPV45无统计学显著性。
  • 所有型别GMC在12和24月下降,但HPV16/18仍保持高水平,7至12月间其他型别GMC下降更明显。
  • 疫苗型别高亲和力抗体至24月分别为75%、76-78%、81-82%(7、12、24月),其他型别分别为16-29%、20-32%、19-32%。

关键数值与推荐

  • 疫苗型别HPV16/18血清阳性率24月为100%。
  • 疫苗型别高亲和力抗体比例7、12、24月分别为75%、76-78%、81-82%。
  • 其他型别高亲和力抗体比例7、12、24月分别为16-29%、20-32%、19-32%。

临床怎么用

  • 支持两剂双价HPV疫苗在24月内对HPV16/18维持高血清阳性率和高亲和力抗体。
  • 对其他型别的交叉保护抗体亲和力较低,需关注长期保护持续时间。

局限性

  • 样本量较小(n=56),随访至24月,需进一步随访观察抗体与亲和力动力学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination. METHODS: A blood sample at 7, 12 and 24 months after the first dose and questionnaire data were collected (n = 56). HPV type-specific antibody concentrations (lU/ml) against seven types (HPV16/18/31/33/45/52/58) were assessed using a validated virus-like particles (VLP) multiplex immunoassay. Avidity was tested using a modification of this assay. RESULTS: Seropositivity for vaccine types HPV 16 and 18 was 100% up to month 24, but declined for HPV-types 31/33/45/52/58, although not statistically significant for HPV45. All Geometric Mean Concentrations (GMCs) declined by months 12 and 24, but remained high for HPV16/18. Between month 7 and 12, GMCs declined more for other types. High avidity antibodies were induced up to 24 months for vaccine types (75%, 76-78% and 81-82% at months 7, 12 and 24, respectively), but for other types antibody avidity was 16-29% at month 7, 20-32% at month 12 and 19-32% at month 24. CONCLUSIONS: GMCs declined over time for HPV-types 16/18/31/33/45/52/58, but remained high for vaccine-types HPV16/18 up to 24 months of follow-up. Antibody avidity was >75% for vaccine types but <35% for other HPV-types. Further follow-up of this cohort will provide insight into antibody and avidity kinetics over time.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Schurink-van 't Klooster TM, Donken R, Schepp RM, et al. Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule. Vaccine. 2018. PMID: 30377068. doi:10.1016/j.vaccine.2018.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。